Compare Stocks: MNPR, ZLAB, IMNM, and CDNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$53.83 -0.8%	$45.32	$13.95 ▼ $55.16	$2.81B	2.43	1.05 million shs	1.38 million shs
IMNM Immunome	$23.97 +0.2%	$25.33	$9.27 ▼ $30.06	$2.72B	2.13	888,714 shs	3.96 million shs
MNPR Monopar Therapeutics	$96.47 -6.1%	$111.72	$50.07 ▼ $124.82	$689.34M	1.49	133,432 shs	382,774 shs
ZLAB Zai Lab	$25.70 -0.4%	$23.22	$15.96 ▼ $34.72	$2.94B	0.83	850,415 shs	887,483 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	-0.83%	+7.10%	+15.74%	+105.61%	+276.43%
IMNM Immunome	+0.17%	-2.84%	-19.64%	+27.91%	+166.63%
MNPR Monopar Therapeutics	-6.07%	-12.51%	-22.10%	+42.49%	+44.76%
ZLAB Zai Lab	-0.43%	+6.46%	-3.82%	+41.36%	-21.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$53.83 -0.8%	$45.32	$13.95 ▼ $55.16	$2.81B	2.43	1.05 million shs	1.38 million shs
IMNM Immunome	$23.97 +0.2%	$25.33	$9.27 ▼ $30.06	$2.72B	2.13	888,714 shs	3.96 million shs
MNPR Monopar Therapeutics	$96.47 -6.1%	$111.72	$50.07 ▼ $124.82	$689.34M	1.49	133,432 shs	382,774 shs
ZLAB Zai Lab	$25.70 -0.4%	$23.22	$15.96 ▼ $34.72	$2.94B	0.83	850,415 shs	887,483 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	-0.83%	+7.10%	+15.74%	+105.61%	+276.43%
IMNM Immunome	+0.17%	-2.84%	-19.64%	+27.91%	+166.63%
MNPR Monopar Therapeutics	-6.07%	-12.51%	-22.10%	+42.49%	+44.76%
ZLAB Zai Lab	-0.43%	+6.46%	-3.82%	+41.36%	-21.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDNA CareDx	2.63	Moderate Buy	$51.20	-4.89% Downside
IMNM Immunome	2.85	Moderate Buy	$34.64	44.50% Upside
MNPR Monopar Therapeutics	2.86	Moderate Buy	$120.08	24.48% Upside
ZLAB Zai Lab	2.71	Moderate Buy	$37.25	44.94% Upside

Current Analyst Ratings Breakdown

Latest MNPR, ZLAB, IMNM, and CDNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	MNPR Monopar Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$128.00 ➝ $145.00
9/10/2026	IMNM Immunome	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/2/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$65.00
9/2/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$65.00
8/17/2026	MNPR Monopar Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$130.00
8/13/2026	CDNA CareDx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C)
8/13/2026	MNPR Monopar Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$125.00 ➝ $128.00
8/13/2026	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$109.00 ➝ $119.00
8/13/2026	MNPR Monopar Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2026	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$31.00 ➝ $35.00
8/12/2026	IMNM Immunome	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDNA CareDx	$379.80M	7.33	$0.01 per share	8,333.59	$5.89 per share	9.14
IMNM Immunome	$6.94M	392.29	N/A	N/A	$5.75 per share	4.17
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$20.62 per share	N/A
ZLAB Zai Lab	$460.16M	6.35	N/A	N/A	$6.39 per share	4.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDNA CareDx	-$21.35M	$2.07	26.00	85.44	N/A	24.23%	2.87%	2.17%	11/3/2026 (Estimated)
IMNM Immunome	-$212.39M	-$2.53	N/A	N/A	N/A	N/A	-50.56%	-46.93%	11/5/2026 (Estimated)
MNPR Monopar Therapeutics	-$13.72M	-$2.17	N/A	N/A	N/A	N/A	-13.08%	-12.79%	11/12/2026 (Estimated)
ZLAB Zai Lab	-$175.54M	-$1.71	N/A	N/A	N/A	-41.86%	-27.43%	-16.72%	11/5/2026 (Estimated)

Latest MNPR, ZLAB, IMNM, and CDNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	MNPR Monopar Therapeutics	-$0.6425	-$0.62	+$0.0225	-$0.7920	N/A	N/A
8/11/2026	Q2 2026	IMNM Immunome	-$0.5138	-$0.65	-$0.1362	-$0.65	$0.17 million	N/A
8/6/2026	Q2 2026	ZLAB Zai Lab	-$0.6794	-$0.46	+$0.2194	-$0.50	$103.87 million	$106.31 million
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million
6/30/2026	Q2 2026	ZLAB Zai Lab	N/A	-$0.50	N/A	-$0.50	N/A	$106.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDNA CareDx	N/A	4.58	4.51
IMNM Immunome	N/A	15.08	15.08
MNPR Monopar Therapeutics	N/A	33.56	33.56
ZLAB Zai Lab	N/A	2.13	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDNA CareDx	N/A
IMNM Immunome	44.58%
MNPR Monopar Therapeutics	1.83%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
CDNA CareDx	2.40%
IMNM Immunome	7.21%
MNPR Monopar Therapeutics	9.70%
ZLAB Zai Lab	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDNA CareDx	765	51.73 million	50.49 million	Optionable
IMNM Immunome	177	113.58 million	105.39 million	Optionable
MNPR Monopar Therapeutics	22	6.71 million	6.06 million	Not Optionable
ZLAB Zai Lab	1,784	113.78 million	108.23 million	Optionable

MNPR, ZLAB, IMNM, and CDNA Headlines

Recent News About These Companies

Zai Lab Limited (ZLAB)

September 11, 2026 | finance.yahoo.com

Seven Fleet Capital Management LP Acquires 58,158 Shares of Zai Lab Limited Unsponsored ADR $ZLAB

September 5, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Down 4.6% - Here's What Happened

September 4, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Trading Up 6.9% - Still a Buy?

September 2, 2026 | marketbeat.com

Zai Lab Limited Unsponsored ADR $ZLAB Stock Position Boosted by Headlands Technologies LLC

September 1, 2026 | marketbeat.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Brokerages

August 29, 2026 | marketbeat.com

Z.ai shares surge 8% after releasing new AI model running only on Chinese chips

August 26, 2026 | cnbc.com

Zai Lab: Revenue Growth And Zoci's Upside Optionality

August 19, 2026 | seekingalpha.com

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026 | businesswire.com

Zai Lab (NASDAQ:ZLAB) CFO Sells 619 Shares

August 14, 2026 | insidertrades.com

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?

August 10, 2026 | finance.yahoo.com

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Zai Lab Limited 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

August 6, 2026 | zacks.com

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

August 6, 2026 | businesswire.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of “Moderate Buy” from Analysts

August 4, 2026 | defenseworld.netD

U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

August 3, 2026 | finance.yahoo.com

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

July 22, 2026 | businesswire.com

Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 7,026 Shares

July 2, 2026 | insidertrades.com

Zai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer Therapy

June 30, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR, ZLAB, IMNM, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

$53.83 -0.45 (-0.83%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$54.00 +0.17 (+0.32%)

As of 09/18/2026 07:30 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Immunome NASDAQ:IMNM

$23.97 +0.04 (+0.17%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$24.05 +0.08 (+0.33%)

As of 09/18/2026 07:30 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Monopar Therapeutics NASDAQ:MNPR

$96.47 -6.23 (-6.07%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$96.19 -0.28 (-0.29%)

As of 09/18/2026 07:30 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Zai Lab NASDAQ:ZLAB

$25.70 -0.11 (-0.43%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$25.70 +0.00 (+0.02%)

As of 09/18/2026 07:30 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNPR, ZLAB, IMNM, and CDNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNPR, ZLAB, IMNM, and CDNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNPR, ZLAB, IMNM, and CDNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR, ZLAB, IMNM, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

Immunome NASDAQ:IMNM

Monopar Therapeutics NASDAQ:MNPR

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNPR, ZLAB, IMNM, and CDNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNPR, ZLAB, IMNM, and CDNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNPR, ZLAB, IMNM, and CDNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR, ZLAB, IMNM, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

Immunome NASDAQ:IMNM

Monopar Therapeutics NASDAQ:MNPR

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools